Robert Vonderheide
MD, DPhil
Director, Abramson Cancer Center
👥Biography 个人简介
Robert Vonderheide pioneered anti-CD40 agonist antibody trials in pancreatic cancer, demonstrating that CD40 agonism can reprogram myeloid cells and prime T cell responses. His work established CD40 agonism as a leading strategy to convert immune-cold pancreatic tumors into immune-hot lesions. He leads the Penn cancer immunotherapy program.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Robert Vonderheide 的研究动态
Follow Robert Vonderheide's research updates
留下邮箱，当我们发布与 Robert Vonderheide（University of Pennsylvania）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment